1. Zuber J, Fakhouri F, Roumenina LT, et al. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol. 2012;8:643–57.
2. US FDA. Scientific considerations in demonstrating biosimilarity to a reference product. https://www.fda.gov/media/82647/download. Accessed 26 Sep 2022.
3. US FDA. Development of therapeutic protein biosimilars: comparative analytical assessment and other quality-related considerations. https://www.fda.gov/media/159261/download. Accessed 26 Sep 2022.
4. European Medicines Agency. Soliris. Summary of product characteristics. 2020. europa.eu. https://www.ema.europa.eu/en/medicines/human/EPAR/soliris. Accessed 8 Aug 2022.
5. European Medicines Agency. Guideline on similar biological medicinal products (revision 1). 2014. europa.eu. https://www.ema.europa.eu/en/similar-biological-medicinal-products-scientific-guideline. Accessed 26 Sept 2022.